ATNG Acquires Patent for Human Blood Bacterium

ATNG Inc. have announced the purchase of a patent from Pathobiotek Inc. which reports a newly-identified human blood bacterium (HBB), and provides characterization, culturing and diagnostic methodologies and methods for the treatment of pathophysiological states caused by the bacterium.

The bacterium is apparently present in the blood stream of all humans in very low numbers, and appears to be directly or indirectly associated with several diseases such as chronic fatigue syndrome, multiple sclerosis and other “autoimmune” diseases.